1 – 10 of 12
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?
(
- Contribution to journal › Scientific review
- 2022
-
Mark
Applying key learnings from the EMAX trial to clinical practice and future trial design in COPD
(
- Contribution to journal › Scientific review
- 2021
-
Mark
Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD : A Prespecified Analysis of The EMAX Trial
(
- Contribution to journal › Article
-
Mark
Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening : a post hoc analysis of the EMAX trial
(
- Contribution to journal › Article
-
Mark
Dual bronchodilator therapy as first-line treatment in maintenance-naïve patients with symptomatic copd : A pre-specified analysis of the emax trial
(
- Contribution to journal › Article
-
Mark
Wtreatment of copd with long-acting bronchodilators : Association between early and longer-term clinically important improvement
(
- Contribution to journal › Article
-
Mark
Non-exacerbating patients with COPD from a UK perspective using the galaxy model
(
- Contribution to journal › Article
- 2020
-
Mark
Predicting the rate of oxygen consumption during the 3-minute constant-rate stair stepping and shuttle tests in people with chronic obstructive pulmonary disease
(
- Contribution to journal › Article
-
Mark
Early and sustained symptom improvement with umeclidinium/vilanterol versus monotherapy in COPD : a post hoc analysis of the EMAX randomised controlled trial
(
- Contribution to journal › Article
-
Mark
Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators : an analysis of the EMAX randomised controlled trial
(
- Contribution to journal › Article